Page 35 - GPD-4-2
P. 35
Gene & Protein in Disease lncRNAs dysregulation in diabetes and its complications
89. Tamgue O, Mezajou CF, Ngongang NN, et al. Non-coding 2015;87:15-24.
RNAs in the etiology and control of major and neglected doi: 10.1016/j.addr.2015.05.012
human tropical diseases. Front Immunol. 2021;12:703936.
100. Liu J, Yao J, Li X, et al. Pathogenic role of lncRNA-MALAT1
doi: 10.3389/fimmu.2021.703936
in endothelial cell dysfunction in diabetes mellitus. Cell
90. Wang H, Xia Y, Zhang Y. Diagnostic significance of Death Dis. 2014;5(10):e1506
serum lncRNA HOTAIR and its predictive value for the doi: 10.1038/cddis.2014.466
development of chronic complications in patients with
type 2 diabetes mellitus. Diabetol Metab Syndr. 2021;13:97. 101. Liu P, Jia SB, Shi JM, et al. LncRNA-MALAT promotes
1
neovascularization in diabetic retinopathy through
doi: 10.1186/s13098-021-00719-3
regulating miR-125b/VE-cadherin axis. Biosci
91. Chang W, Wang J. Exosomes and their noncoding RNA Rep. 2019;39(5):BSR20181469.
cargo are emerging as new modulators for diabetes mellitus.
Cells. 2019;8(8):853. doi: 10.1042/BSR20181469
102. Shi S, Song L, Yu H, et al. Knockdown of LncRNA-H19
doi: 10.3390/cells8080853
ameliorates kidney fibrosis in diabetic mice by
92. Sanchez-Parra C, Jacovetti C, Dumortier O, et al. suppressing miR-29a-mediated EndMT. Front Pharmacol.
Contribution of the long noncoding RNA H19 to β-cell 2020;11:586895.
mass expansion in neonatal and adult rodents. Diabetes.
2018;67(11):2254-2267. doi: 10.3389/fphar.2020.586895
doi: 10.2337/db18-0201 103. Zhang W, Cao D, Wang Y, Ren W. LncRNA MEG8 is
upregulated in gestational diabetes mellitus (GDM)
93. Fawzy MS, Abdelghany AA, Toraih EA, Mohamed AM. and predicted kidney injury. J Diabetes Complications.
Circulating long noncoding RNAs H19 and GAS5 are 2021;35(1):107749.
associated with type 2 diabetes but not with diabetic
retinopathy: A preliminary study. Bosn J Basic Med Sci. doi: 10.1016/j.jdiacomp.2020.107749
2020;20(3):365-371. 104. Zhao C, Hu J, Wang Z, Cao ZY, Wang L. Serum LncRNA
doi: 10.17305/bjbms.2019.4533 PANDAR may act as a novel serum biomarker of diabetic
nephropathy in patients with type 2 diabetes. Clin Lab.
94. Zhu X, Wu YB, Zhou J, Kang DM. Upregulation of lncRNA 2020;66(6).
MEG3 promotes hepatic insulin resistance via increasing
FoxO1 expression. Biochem Biophys Res Commun. doi: 10.7754/Clin.Lab.2019.191032
2016;469(2):319-325. 105. Li S, Li Y, Chen B, et al. exoRBase: A database of circRNA,
doi: 10.1016/j.bbrc.2015.11.048 lncRNA and mRNA in human blood exosomes. Nucleic
Acids Res. 2018;46(D1):D106-D112.
95. Tello-Flores VA, Beltrán-Anaya FO, Ramírez-Vargas MA,
et al. Role of long non-coding RNAs and the molecular doi: 10.1093/nar/gkx891
mechanisms involved in insulin resistance. Int J Mol Sci. 106. Peng L, Yuan X, Jiang B, Tang Z, Li GC. LncRNAs: Key
2021;22(14):7256. players and novel insights into cervical cancer. Tumor Biol.
doi: 10.3390/ijms22147256 2016;37:2779-2788.
96. Rashidmayvan M, Sahebi R, Ghayour-Mobarhan M. Long doi: 10.1007/s13277-015-4663-9
non-coding RNAs: A valuable biomarker for metabolic 107. Széll M, Danis J, Bata-Csörgő Z, Kemény L. PRINS, a
syndrome. Mol Genet Genomics. 2022;297(5):1169-1183. primate-specific long non-coding RNA, plays a role in the
doi: 10.1007/s00438-022-01922-1 keratinocyte stress response and psoriasis pathogenesis.
Pflügers Arch. 2016;468:935-943.
97. Zhang Y, Wu H, Wang F, Ye M, Zhu H, Bu S. Long non‐
coding RNA MALAT expression in patients with gestational doi: 10.1007/s00424-016-1803-z
1
diabetes mellitus. Int J Gynecol Obstet. 2018;140(2):164-169. 108. Yang Y, Cai Y, Wu G, et al. Plasma long non-coding RNA,
doi: 10.1002/ijgo.12384 CoroMarker, a novel biomarker for diagnosis of coronary
artery disease. Clin Sci. (Lond). 2015;129(8):675-685.
98. Saleh RO, Al-Ouqaili MTS, Ali E, et al. lncRNA-microRNA
axis in cancer drug resistance: Particular focus on signaling doi: 10.1042/CS20150121
pathways. Med Oncol. 2024;41(2):52.
109. Kaur S, Mirza AH, Brorsson CA, et al. The genetic
doi: 10.1007/s12032-023-02263-8 and regulatory architecture of ERBB3-type 1 diabetes
susceptibility locus. Mol Cell Endocrinol. 2016;419:83-91.
99. Khorkova O, Hsiao J, Wahlestedt C. Basic biology and
therapeutic implications of lncRNA. Adv Drug Deliv Rev. doi: 10.1016/j.mce.2015.10.002
Volume 4 Issue 2 (2025) 15 doi: 10.36922/gpd.4000

